This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone revenue falls 79 percent as quarterly profit turns to loss
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250 and 2.4 pts more than its Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone revenue from operations in the quarter ended 30 September 2026 fell 79 percent to Rs 16 lakh from Rs 76.74 lakh a year earlier; it posted a loss after tax of Rs 8.08 lakh versus a profit of Rs 1.41 lakh. Operating margin before interest, tax, depreciation and amortisation fell from about minus 52 percent to minus 252 percent. Standalone half-year revenue was Rs 158.99 lakh; loss after tax was Rs 65.40 lakh. Prior figures were recast.
The sales fall and quarterly loss hurt sentiment. Rs 1.10 lakh cash versus Rs 1,100 lakh borrowings raises liquidity concerns despite positive equity.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹0.16 Cr | ₹0.77 Cr | −79.2% |
| Operating profit | −₹0.40 Cr | −₹0.40 Cr | loss widened |
| Profit after tax | −₹0.08 Cr | ₹0.01 Cr | −673.8% |
| EBITDA margin | -252.3% | -51.6% | −200.7 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.